{"entity":{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","aka":["Pieris AG","NASDAQ:PIRS"],"tldr":"Pieris Pharmaceuticals engineered small lipocalin proteins called Anticalins into cancer immunotherapies, including the HER2-targeted 4-1BB agonist cinrebafusp alfa, before merging into Palvella Therapeutics in 2024.","summary":"Pieris Pharmaceuticals, founded in Freising, Germany and later headquartered in Boston, developed Anticalin proteins, engineered derivatives of human lipocalins, as an alternative to antibodies. Its oncology lead, cinrebafusp alfa (PRS-343), fused a HER2 antibody to a 4-1BB-binding Anticalin so that T-cell costimulation happened only in HER2-positive tumours; a phase 2 study in HER2-positive gastric cancer was halted in 2023 for strategic reasons. The company completed a reverse merger with Palvella Therapeutics in December 2024.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["cinrebafusp-alfa"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Boston, Massachusetts","country":"US","companyType":"biotech","founded":2001,"stage":"acquired","investors":[],"funding":[]},"route":"/companies/pieris-pharmaceuticals/","neighbours":{"drug":[{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/"}]}}